Experimental Weight Loss and Diabetes Drug in Clinical Trials

Diabetes and obesity are closely linked, and plenty of diabetics struggle to follow their doctor's orders to lose weight. The biopharmaceutical company Vivus hopes to promote an investigational new drug, Qnexa, as each a weight loss drug and a diabetes medication.

Qnexa is in section three clinical trials to treat obesity, and in section a pair of clinical development for the treatment of sort a pair of diabetes and sleep apnea. the foremost recent clinical trial of Qnexa as a weight loss drug resulted in a mean ten % weight loss in study participants.

Qnexa may be a combination of the appetite suppressant phentermine, (best referred to as the "phen" in fen-phen, a controversial weight loss drug that was achieved the market in 1997), and also the anticonvulsant topiramate, prescribed to treat epilepsy and stop migraine headaches.

Qnexa was denied approval in late 2010, when the FDA expressed considerations a couple of slightly increased risk of adverse psychiatric and cardiovascular events, and questioned the likelihood of birth defects in pregnant ladies taking the drug.

More than 2400 patients took half within the latest study. Study participants were all clinically obese, and conjointly suffered from 2 or a lot of secondary medical conditions like diabetes or heart disease. Patients conjointly saw enhancements in high blood pressure, cholesterol and A1C levels (glycated hemoglobin). High A1C levels indicate high levels of blood glucose in diabetics.

Shares of Vivus have increased up to sixteen % in worth since the most recent study results were released.  If approved, Qnexa would be the primary new weight loss drug on the market in additional than 10 years. Currently, the sole FDA approved prescription weight loss drug is orlistat (Zenical). Orlistat prevents the body from absorbing the fat in food, and is thought for unpleasant aspect effects like loose, oily stools, fecal incontinence and flatulence.

A second weight-loss drug manufacturer, Orexigen, is additionally struggling to induce FDA approval for his or her new diet drug, Contrave. Contrave may be a combination of bupropion (the antidepressant Wellbutrin, conjointly marketed because the smoking cessation aid Zyban) and naltrexone, an opiate antagonist prescribed to treat narcotic and alcohol addiction. Contrave is meant to curb food cravings, and proved effective than Qnexa in terms of weight loss.

Contrave passed a significant hurdle in late 2010 when an FDA advisory committee voted 13-7 for its approval, however the FDA disagreed in early 2011, soliciting for a brand new clinical trial evaluating the drug's cardiovascular risks.

Arena Pharmaceutical's Lorcaserin was the third diet drug to fail to win FDA approval in 2010, when the FDA deemed that safety considerations outweighed the drug's "marginal effectiveness".

Incoming search terms

diabetes medications,diabetes drug,diabetes medication,long acting insulin,lantus solostar,canadian pharmacy,big mountain medication

Muscle Pattern Recognition System Approved by Health Canada

Health Canada has recently approved iTech Medical for his or her Muscle Pattern Recognition (MPR) System, that could be a clinical assessment technology to assist with the diagnosis and treatment of back and neck pain. Back and neck pain is one amongst the foremost frequently diagnosed chronic conditions in Canada. The diagnosis and treatment neck and back pain could be a terribly expensive drawback in Canada. Up to four-hundredth of all day without work work are thought to be attributable to chronic back or neck pain. The reason for the pain is usually tough to grasp, and in most cases the cause can not be identified. This new Muscle Pattern Recognition system will facilitate to spot what causes chronic back and neck pain, which is able to additionally facilitate scale back medical expenses.

iTech Medical believe that "patients, physicians and insurance suppliers stand to profit from our Muscle Pattern Recognition (MPR) technology," said Karl Wolcott, who is that the vice chairman of Sales and selling for iTech Medical. They confirmed that they're in discussions with partners in Canada to ‘suss out' the market and start selling the new technology to Canadian medical suppliers.

Online Canadian Pharmacy's Role In Back and Neck Pain

Until the new iTech Medical technology is obtainable, patients can still be treated for chronic back and neck pain with the employment of pain medication, that though doesn't treat the cause it will relieve patients of symptoms together with aching and pain, that means that they'll go regarding their lives as traditional while not an excessive amount of result. Pain medications from Canada pharmacies on-line like BigMountainDrugs.com are offered at lower costs than in America, and are conveniently sent direct to you thru the mail. This cross-border medication buying has long been established attributable to the high costs for medication within the US. huge Mountain medicine try to supply the simplest costs for a spread of medicines, together with pain medications to assist with the relief of back and neck pain together with Panadol, Robaxin, Avage and Relafen. it's a licensed on-line Canada pharmacywho continually asks for a prescription for RX medicine, creating them a trustworthy on-line pharmacy.
Big Mountain Drug additionally advocate that patients with chronic back and neck pain get alternative recommendation from physicians like a physiotherapist who will facilitate with chronic pain within the back and neck. obtaining regular exercise may also facilitate by strengthening the muscles within the back, however it's vital to be light so as to avoid additional harm to the muscles.

Buy Canada medicine Safely With on-line Pharmacies

Big Mountain medicine are a licensed on-line pharmacy and are verified by the Canada International Pharmacy Association and Pharmacy Checker. each of those associations aim to confirm the protection of patients who are shopping for Canada medicine on-line by confirming the company's license data similarly as checking contact data, and guaranteeing that the location is secure. GeoTrust supply security of private data given on the large Mountain medicine web site, and McAfee Secure protects the location against hacking and phishing, therefore you recognize that you just are in safe hands.

Incoming search terms

canada pharmacy,canada medicine on-line,big mountain medicine

Eating Too Quickly Doubles the Risk of Insulin Resistance

Yet another reason to listen to your mother and slow down and chew your food properly - eating too quickly has been associated with a doubled risk of developing impaired glucose tolerance, or pre-diabetes. As the name suggests, pre-diabetes is the forerunner to developing type 2 diabetes. Most diabetics have type 2 diabetes – a form of diabetes where your body no longer responds properly to insulin (called insulin resistance). Type 2 diabetes used to be described as non insulin dependent diabetes.

Insulin is the hormone that moves sugar (glucose) from the blood to the body's cells to provide them with energy. If your cells do not use insulin properly, the pancreas produces more insulin that normal to cope with the body's demands. Eventually, the pancreas cannot keep up, and excess glucose builds up in the bloodstream. Type 2 diabetes is characterized by high levels of glucose in the blood.

A recent Japanese study followed over 170 healthy individuals for three years, monitoring their eating habits. Snacking, eating late at night, skipping meals and eating out were not associated with developing pre-diabetes. The one and only eating habit associated with the development of insulin resistance was eating too quickly.

The researchers aren't sure why eating faster makes an individual more likely to develop pre-diabetes and type 2 diabetes, but suspect that eating rapidly results in higher post-meal blood glucose levels.  Some doctors also point out that eating too quickly results in an overall increase in the amount of calories taken in, and a resulting weight gain. Since it takes about 20 minutes for the brain to receive the signal that the stomach is full, those who eat quickly continue eating without realizing that their stomach is filled.

Previous research has also shown that eating quickly results in increased weight gain. Insulin resistance generally increases with increased body fat, and there is a pronounced connection between obesity and diabetes. The two are so closely connected that it gave rise to the term "diabesity". Diabesity is currently epidemic across the developed world.

Insulin resistance has no symptoms. Pre-diabetes is sometimes called impaired glucose tolerance, and can be diagnosed with a fasting glucose test or a glucose tolerance test. The American Diabetes Association recommends that adults who are overweight and have one or more additional risk factors for diabetes should consider being tested. Additional risk factors include:

• Having a parent or sibling with diabetes
• Being physically inactive.
• Being African American,Alaskanative, American Indian, Asian American, Hispanic or Latino, or a Pacific Islander
• Giving birth to a baby weighing more than 9 pounds or being diagnosed with gestational diabetes
• Having high blood pressure or being treated for high blood pressure
• Low HDL ("good") cholesterol levels or high triglyceride levels
• Having polycystic ovary syndrome
• Having a history of cardiovascular disease

People with pre-diabetes can avoid becoming diabetic and having to take diabetes medication by losing weight, being physically active, eating a healthy diet, and, as we now know, not eating too quickly.

Incoming search terms

insulin resistance,insulin dependent,diabetes medication,long acting insulin,big mountain drugs,canadian pharmacy,buy lantus,lantus solostar

Experimental Weight Loss and Diabetes Drug in Clinical Trials

Diabetes and obesity are closely linked, and lots of diabetics struggle to follow their doctor's orders to lose weight. The biopharmaceutical company Vivus hopes to plug an investigational new drug, Qnexa, as each a weight loss drug and a diabetes medication.

Qnexa is in section three clinical trials to treat obesity, and in section a pair of clinical development for the treatment of sort a pair of diabetes and sleep apnea. the foremost recent clinical trial of Qnexa as a weight loss drug resulted in a mean ten p.c weight loss in study participants.

Qnexa may be a combination of the appetite suppressant phentermine, (best referred to as the "phen" in fen-phen, a controversial weight loss drug that was done the market in 1997), and therefore the anticonvulsant topiramate, prescribed to treat epilepsy and stop migraine headaches.

Qnexa was denied approval in late 2010, when the FDA expressed issues a couple of slightly increased risk of adverse psychiatric and cardiovascular events, and questioned the chance of birth defects in pregnant girls taking the drug.

More than 2400 patients took half within the latest study. Study participants were all clinically obese, and conjointly suffered from 2 or a lot of secondary medical conditions like diabetes or heart disease. Patients conjointly saw enhancements in high blood pressure, cholesterol and A1C levels (glycated hemoglobin). High A1C levels indicate high levels of blood glucose in diabetics.

Shares of Vivus have increased up to sixteen p.c in price since the most recent study results were released.  If approved, Qnexa would be the primary new weight loss drug on the market in additional than 10 years. Currently, the sole FDA approved prescription weight loss drug is orlistat (Zenical). Orlistat prevents the body from absorbing the fat in food, and is understood for unpleasant aspect effects like loose, oily stools, fecal incontinence and flatulence.

A second weight-loss drug manufacturer, Orexigen, is additionally struggling to induce FDA approval for his or her new diet drug, Contrave. Contrave may be a combination of bupropion (the antidepressant Wellbutrin, conjointly marketed because the smoking cessation aid Zyban) and naltrexone, an opiate antagonist prescribed to treat narcotic and alcohol addiction. Contrave is intended to curb food cravings, and proved effective than Qnexa in terms of weight loss.

Contrave passed a significant hurdle in late 2010 when an FDA advisory committee voted 13-7 for its approval, however the FDA disagreed in early 2011, requesting a replacement clinical trial evaluating the drug's cardiovascular risks.

Arena Pharmaceutical's Lorcaserin was the third diet drug to fail to win FDA approval in 2010, when the FDA deemed that safety issues outweighed the drug's "marginal effectiveness".

Incoming search terms

diabetes medications,diabetes drug,diabetes medication,long acting insulin,lantus solostar,canadian pharmacy,big mountain medication

SmartPill Helps with Diagnosing Diabetes and Gastroparesis

New technology is permitting doctors to diagnose gastrointestinal disorders easier than ever before. The SmartPill GI Monitoring System may be a capsule monitoring device that's ingested by the patient at the doctor's workplace. The patient is then fitted with the wireless knowledge receiver. The receiver may be hooked up to the patient's belt for simple mobility. The SmartPill capsule, that is regarding the dimensions of an outsized multivitamin, may be simply worked through the gastrointestinal tract. whereas on its "travels" the SmartPill collects knowledge like pressure, pH and temperature levels, that are sent to the wireless receiver. This knowledge is then employed by the doctor to see the disorder that the patient is suffering.

The SmartPill procedure is meant to exchange pricey and invasive procedures to see the explanation for gastrointestinal symptoms. Patients who have experienced unexplained vomiting, abdomen spasms or bloating will relax currently that they are doing not have to be compelled to bear surgery.

 Diabetics especially are a lot of probably to want this diagnosing system. owing to their totally different digestive systems, diabetics are a lot of vulnerable to gastrointestinal tract disorders. The SmartPill system are going to be ready to facilitate doctors higher evaluate and diagnose their diabetic patients.

The SmartPill GI Monitoring System are going to be notably useful in diagnosing disorders like gastroparesis, that is delayed abdomen emptying. Gastroparesis affects countless Americans each year, particularly those with existing disorders like diabetes or irritable bowel syndrome.

 For diabetics, gastroparesis makes controlling blood sugar levels harder, as a delay in digestion causes blood glucose levels to rapidly rise when food enters the tiny intestine. This causes glucose levels to be erratic and tough to manage.

 Once the patient's SmartPill results are examined, doctors will a lot of effectively diagnose the symptoms, and a lot of exactly prescribe what's required. For gastroparesis, doctors usually prescribe Motilium, or its generic equivalent, domperidone. Domperidone, a dopamine antagonist, works on the gastrointestinal tract by each promoting gastric movement and easing gastroparesis symptoms. These effects are created by works by blocking the action of a chemical messenger within the brain that causes the sensation of nausea and vomiting, likewise as by increasing the movement or contractions of the abdomen and intestines, permitting food to maneuver a lot of simply through the abdomen.

Incoming search terms

buy lantus,buy motilium,motilium,domperidone,gastroparesis,diabetes,doctors,patients,canadian on-line pharmacy,big mountain medication

Experimental Weight Loss and Diabetes Drug in Clinical Trials

Diabetes and obesity are closely linked, and plenty of diabetics struggle to follow their doctor's orders to lose weight. The biopharmaceutical company Vivus hopes to promote an investigational new drug, Qnexa, as each a weight loss drug and a diabetes medication.

 

Qnexa is in part three clinical trials to treat obesity, and in part a pair of clinical development for the treatment of kind a pair of diabetes and sleep apnea. the foremost recent clinical trial of Qnexa as a weight loss drug resulted in a mean ten p.c weight loss in study participants.

 

Qnexa may be a combination of the appetite suppressant phentermine, (best called the "phen" in fen-phen, a controversial weight loss drug that was attained the market in 1997), and also the anticonvulsant topiramate, prescribed to treat epilepsy and stop migraine headaches.

 

Qnexa was denied approval in late 2010, when the FDA expressed issues a couple of slightly increased risk of adverse psychiatric and cardiovascular events, and questioned the chance of birth defects in pregnant ladies taking the drug.

 

More than 2400 patients took half within the latest study. Study participants were all clinically obese, and conjointly suffered from 2 or a lot of secondary medical conditions like diabetes or heart disease. Patients conjointly saw enhancements in high blood pressure, cholesterol and A1C levels (glycated hemoglobin). High A1C levels indicate high levels of blood glucose in diabetics.

 

Shares of Vivus have increased up to sixteen p.c in worth since the most recent study results were released.  If approved, Qnexa would be the primary new weight loss drug on the market in additional than 10 years. Currently, the sole FDA approved prescription weight loss drug is orlistat (Zenical). Orlistat prevents the body from absorbing the fat in food, and is understood for unpleasant facet effects like loose, oily stools, fecal incontinence and flatulence.

 

A second weight-loss drug manufacturer, Orexigen, is additionally struggling to induce FDA approval for his or her new diet drug, Contrave. Contrave may be a combination of bupropion (the antidepressant Wellbutrin, conjointly marketed because the smoking cessation aid Zyban) and naltrexone, an opiate antagonist prescribed to treat narcotic and alcohol addiction. Contrave is intended to curb food cravings, and proved effective than Qnexa in terms of weight loss.

 

Contrave passed a significant hurdle in late 2010 when an FDA advisory committee voted 13-7 for its approval, however the FDA disagreed in early 2011, requesting a brand new clinical trial evaluating the drug's cardiovascular risks.

 

Arena Pharmaceutical's Lorcaserin was the third diet drug to fail to win FDA approval in 2010, when the FDA deemed that safety issues outweighed the drug's "marginal effectiveness".

Incoming search terms

diabetes medications,diabetes drug,diabetes medication,long acting insulin,lantus solostar,canadian pharmacy,big mountain medicine

Experimental Weight Loss and Diabetes Drug in Clinical Trials

Diabetes and obesity are closely linked, and many diabetics struggle to follow their doctor's orders to lose weight. The biopharmaceutical company Vivus hopes to market an investigational new drug, Qnexa, as both a weight loss drug and a diabetes medication.

Qnexa is in phase 3 clinical trials to treat obesity, and in phase 2 clinical development for the treatment of type 2 diabetes and sleep apnea. The most recent clinical trial of Qnexa as a weight loss drug resulted in an average 10 percent weight loss in study participants.

Qnexa is a combination of the appetite suppressant phentermine, (best known as the "phen" in fen-phen, a controversial weight loss drug that was pulled off the market in 1997), and the anticonvulsant topiramate, prescribed to treat epilepsy and prevent migraine headaches.

Qnexa was denied approval in late 2010, when the FDA expressed concerns about a slightly increased risk of adverse psychiatric and cardiovascular events, and questioned the possibility of birth defects in pregnant women taking the drug.

More than 2400 patients took part in the latest study. Study participants were all clinically obese, and also suffered from two or more secondary medical conditions such as diabetes or heart disease. Patients also saw improvements in high blood pressure, cholesterol and A1C levels (glycated hemoglobin). High A1C levels indicate high levels of blood glucose in diabetics.

Shares of Vivus have increased up to sixteen percent in value since the latest study results were released. If approved, Qnexa would be the first new weight loss drug on the market in more than ten years. Currently, the only FDA approved prescription weight loss drug is orlistat (Zenical). Orlistat prevents the body from absorbing the fat in food, and is known for unpleasant side effects such as loose, oily stools, fecal incontinence and flatulence.

A second weight-loss drug manufacturer, Orexigen, is also struggling to get FDA approval for their new diet drug, Contrave. Contrave is a combination of bupropion (the antidepressant Wellbutrin, also marketed as the smoking cessation aid Zyban) and naltrexone, an opiate antagonist prescribed to treat narcotic and alcohol addiction. Contrave is designed to curb food cravings, and proved effective than Qnexa in terms of weight loss.

Contrave passed a major hurdle in late 2010 when an FDA advisory committee voted 13-7 for its approval, but the FDA disagreed in early 2011, asking for a new clinical trial evaluating the drug's cardiovascular risks.

Arena Pharmaceutical's Lorcaserin was the third diet drug to fail to win FDA approval in 2010, when the FDA deemed that safety concerns outweighed the drug's "marginal effectiveness".

Incoming search terms


diabetes medications,diabetes drug,diabetes medication,long acting insulin,lantus solostar,canadian pharmacy,big mountain drugs